BridgeBio Pharma (BBIO) Competitors

BridgeBio Pharma logo
$77.36 -0.94 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$77.36 0.00 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BBIO vs. RVMD, BIIB, GMAB, ALNY, and ROIV

Should you buy BridgeBio Pharma stock or one of its competitors? BridgeBio Pharma's main competitors and comparable companies include Revolution Medicines (RVMD), Biogen (BIIB), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Revolution Medicines had 8 more articles in the media than BridgeBio Pharma. MarketBeat recorded 20 mentions for Revolution Medicines and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Revolution Medicines' score of 0.94 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revolution Medicines
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

BridgeBio Pharma currently has a consensus target price of $104.42, indicating a potential upside of 33.36%. Revolution Medicines has a consensus target price of $262.75, indicating a potential upside of 52.50%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A
Revolution Medicines$197.56M188.63-$1.13B-$9.11N/A

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -59.84%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-59.84% N/A -39.81%
Revolution Medicines N/A -84.51%-51.97%

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

Revolution Medicines beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Biogen?

Biogen (NASDAQ:BIIB) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, Biogen had 12 more articles in the media than BridgeBio Pharma. MarketBeat recorded 24 mentions for Biogen and 12 mentions for BridgeBio Pharma. Biogen's average media sentiment score of 1.33 beat BridgeBio Pharma's score of 0.99 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
17 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.9% of Biogen shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biogen has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.79$1.29B$2.34108.29
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A

Biogen has a net margin of 3.37% compared to BridgeBio Pharma's net margin of -59.84%. Biogen's return on equity of 9.38% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
BridgeBio Pharma -59.84%N/A -39.81%

Biogen presently has a consensus price target of $254.41, suggesting a potential upside of 0.40%. BridgeBio Pharma has a consensus price target of $104.42, suggesting a potential upside of 33.36%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Biogen beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Genmab A/S had 7 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for Genmab A/S and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Genmab A/S's score of -0.15 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genmab A/S has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.72B8.62$963M$1.1743.91
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S presently has a consensus target price of $53.50, suggesting a potential upside of 4.15%. BridgeBio Pharma has a consensus target price of $104.42, suggesting a potential upside of 33.36%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82

Genmab A/S has a net margin of 16.97% compared to BridgeBio Pharma's net margin of -59.84%. Genmab A/S's return on equity of 13.67% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S16.97% 13.67% 6.42%
BridgeBio Pharma -59.84%N/A -39.81%

Summary

Genmab A/S beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

BridgeBio Pharma (NASDAQ:BBIO) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Alnylam Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A
Alnylam Pharmaceuticals$3.71B5.95$313.75M$19.268.57

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to BridgeBio Pharma's net margin of -59.84%. Alnylam Pharmaceuticals' return on equity of 155.33% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-59.84% N/A -39.81%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Alnylam Pharmaceuticals' score of 0.44 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

BridgeBio Pharma currently has a consensus price target of $104.42, indicating a potential upside of 33.36%. Alnylam Pharmaceuticals has a consensus price target of $305.86, indicating a potential upside of 85.33%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Alnylam Pharmaceuticals beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

BridgeBio Pharma has a net margin of -59.84% compared to Roivant Sciences' net margin of -838.21%. BridgeBio Pharma's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
BridgeBio Pharma -59.84%N/A -39.81%

In the previous week, Roivant Sciences had 15 more articles in the media than BridgeBio Pharma. MarketBeat recorded 27 mentions for Roivant Sciences and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Roivant Sciences' score of 0.50 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Roivant Sciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Roivant Sciences presently has a consensus target price of $46.64, suggesting a potential upside of 17.98%. BridgeBio Pharma has a consensus target price of $104.42, suggesting a potential upside of 33.36%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82

Roivant Sciences has higher earnings, but lower revenue than BridgeBio Pharma. Roivant Sciences is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BridgeBio Pharma beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBIO vs. The Competition

MetricBridgeBio PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$15.07B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-25.4524.2434.3430.11
Price / Sales15.9414.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book-7.184.354.763.85
Net Income-$724.93M-$24.19M$3.52B$393.14M
7 Day Performance-0.73%-7.26%-5.34%-4.53%
1 Month Performance16.52%-4.96%-3.61%-5.86%
1 Year Performance16.52%-2.87%0.01%-7.78%

BridgeBio Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBIO
BridgeBio Pharma
3.622 of 5 stars
$77.36
-1.2%
$104.42
+35.0%
+17.9%$15.23B$502.08MN/A839
RVMD
Revolution Medicines
3.2207 of 5 stars
$188.17
-1.6%
$242.90
+29.1%
+154.3%$40.45B$11.58MN/A883
BIIB
Biogen
2.9954 of 5 stars
$249.01
-1.8%
$252.34
+1.3%
+51.2%$36.06B$9.89B20.727,500
GMAB
Genmab A/S
2.2674 of 5 stars
$54.92
-3.8%
$53.61
-2.4%
+69.8%$35.61B$4.13B43.243,029
ALNY
Alnylam Pharmaceuticals
4.8655 of 5 stars
$158.00
-4.2%
$305.86
+93.6%
-63.3%$31.10B$3.71B8.202,770

Related Companies and Tools


This page (NASDAQ:BBIO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners